Sage Journals: Discover world-class research

Abstract

On-line real-time drug utilization review (ORDUR) in general, and prospective drug utilization review, specifically, have been embraced conceptually by the health care industry. To date, ORDUR has focused on the avoidance of harmful drug combinations or misuse of medications as a means of both reducing costs and preventing adverse health outcomes. Health care organizations that are responsible for prescription drug benefit programs are able to demonstrate some cost savings as a direct result of implementing ORDUR, which has contributed to its wide acceptance. The limiting factor for the effectiveness of clinical algorithms used in such applications is the type of information available via community pharmacy information systems. Thus, in order to improve the effectiveness of ORDUR screening, additional information is required. Specifically, diagnostic information normally found in patients' medical records is a primary requirement for enhancing the integrity and accuracy of current clinical algorithms. In the near future, decision support tools are likely to be developed which should optimize the usefulness of this information once it becomes available. Before ORDUR can evolve into an integral piece of the pharmacotherapeutic process, in the form of on-line, real-time decision support (ORDS), such additional decision support tools will be necessary.

Keywords

Drug utilization review Decision support Drug safety Prescription claims processing Managed care

Get full access to this article

View all access options for this article.

References

Mugford

Banfield

O'Hanlon

. Effects of feedback of information on clinical practice: A review. BMJ. 1991;303:398–402.

Anon. Electronic Claims Near the 50% Mark. Health Data Network News. 1995;4:1–2.

Bates

Cullen

Laird

. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274(1):29–34.

General Accounting Office. Automated Prospective Review Systems Offer Potential Benefits for Medicaid. Report to the Chairman, House of Representatives (GAO/AIMD-94–130). August 1994:1–31.

Jollis

Ancukiewicz

DeLong

. Discordance of databases designed for claims payment versus clinical information systems: Implications for outcomes research. Ann Intern Med. 1993;119(8):884–850.

Soumerai

Lipton

. Computer-based drug-utilization review — risk, benefit or boondoggle?. N Engl J Med. 1995;332(24):1611–1615.

Leape

Bates

Cullen

. Systems analysis of adverse drug events. JAMA. 1995; 274(1):35–43.

Pearson

Pittman

Longley

. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm. 1994;51:2268–2272.

Bates

O'Neil

Boyle

. Potential identifiability and preventability of adverse events using information systems. J Am Med Informatics Assoc. 1994; 1(5):404–411.

10.

Spitzer

Suissa

Ernst

. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326(8): 501–506.

11.

National Heart, Lung and Blood Institute, National Asthma Education Programs, Expert Panel on the Management of Asthma. Guidelines for Diagnosis and Management of Asthma. Bethesda: National Asthma Education Program, Office of Prevention, Educatioon and Control, National Heart, Lung and Blood Institute, National Institutes of Health; 1991: Publication number 913042.

12.

Ernst

. Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992;268(24):3462–3464.

On-Line,Real-Time Drug Utilization Review: Evolution toward Decision Support

Abstract

Keywords

Get full access to this article

References